Health iQ
leaders in real world data
Introduction
Many life science organisations want to form lasting partnerships with the NHS. It is only natural to set this as a strategic goal since the NHS is the primary customer for so many firms in the UK.
Originally published at Pharmafield
An overwhelming trend in 2018 will be increasing restrictions around releasing healthcare data for analysis, just as we begin to connect with it for deeper insights.
It’s that time of the year again.
You can almost smell it in the air.
The heating is on a timer, festive takeaway cups appear, we’ve ticked off Halloween and Bonfire Night and now all roads lead toward the Christmas and New Year festivities.
By Jilani Gulam | CEO - Chief Executive Officer
I was recently consulted by the Daily Telegraph to provide my thoughts on the future of healthcare and the technologies that are transforming it. Though the article has already been published here, this post is an elaboration of my thinking.
Originally published at pharmaphorum.com
Following the recent publication of the Department of Health’s response document on data security issues, Adam Marsh and Hassan Chaudhury highlight and assess the points that could have an impact on the pharma industry.
Originally published at Pharmafield
There was big news in May when Amgen and Astra Zeneca agreed outcomes-based refunds contracts with Harvard Pilgrim, a respected American health service company.
Originally published at Pharmafield
The Holy Grail for pharma
The Holy Grail for pharmaceutical companies is the ability to demonstrate which patients are likely to respond to innovative treatment, while ensuring timely access and uptake for them with appropriate reimbursement.
Originally published at the PM Society
The PM Society Market Access Interest Group (MAIG) is made up of members from both industry and agency. The Group sent out a short, open survey in late 2016 with the objectives to determine how well Market Access is understood, what the barriers and opportunities were and if possible establish if there is broad uniformity or not in how Market Access is defined.
Originally published at Pharmafield
There is incredible potential in advanced healthcare analytics. Imagine a scenario where we can intervene to save a patient, just before a heart attack occurs, because of predictive modelling with ‘big data’ and ‘machine learning’.
18th April 2017 passed by uneventfully for most people. For us at Health iQ though, this marks an important milestone; 6 years as a company and a journey that has taken us from obscurity to a market leading position.
Originally published at pharmaphorum.com
How the technology behind Bitcoin can facilitate trusted data sharing and unlock innovation in healthcare through distributed ledgers.
Originally published at the PM Society
What the $%^& is Market Access?
Market Access is a contested term, which means that if we put 5 pharma marketeers in a room we’re likely to get 6 opinions.
Originally published at Pharmafield
Hassan Chaudhury, Chief Commercial Officer at Health iQ Limited, on the value of drive, resilience and a lifelong love of learning.
Matching supply and demand with discrete event simulation
The crisis in the NHS has dominated the news agenda. Reports have been consistent across the country of staffing shortages, fewer beds, overcrowded departments, longer wait times and diverted ambulances amidst a backdrop of claims of chronic underfunding undermining care, particularly in emergency settings.